Cipla Propels Lung Leadership Plans, Reimagines Operating Models
Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.
You may also be interested in...
Gilead’s voluntary licensing of remdesivir to five companies while temporarily charging no royalty and allowing them pricing latitude for 127 developing countries not only expands market access but tilts the pricing debate in Gilead’s favor. It also brings significant potential add-on manufacturing capacity.
An early assessment of the impact of COVID-19 on the Indian pharmaceutical market by IQVIA suggests a significant tapering of growth in 2020, along the lines of similar expectations in some other Asian nations. Some industry experts are endorsing the strained outlook, at least for now.
The agency said Cipla’s ANDA met all the requirements for approval, but also that there is increased demand for the products.